Meriem Messaoudene
Overview
Explore the profile of Meriem Messaoudene including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
4381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montegut L, Liu P, Zhao L, Perez-Lanzon M, Chen H, Mao M, et al.
Mol Cancer
. 2024 Oct;
23(1):231.
PMID: 39420364
No abstract available.
2.
Montegut L, Derosa L, Messaoudene M, Chen H, Lambertucci F, Routy B, et al.
Oncoimmunology
. 2024 Oct;
13(1):2413719.
PMID: 39381589
Acyl CoA binding protein (ACBP, which is encoded by , ) acts on the gamma-amino butyric acid (GABA) receptor type A via a specific binding site that is shared by...
3.
Messaoudene M, Ferreira S, Saint-Lu N, Ponce M, Truntzer C, Boidot R, et al.
Nat Commun
. 2024 Sep;
15(1):8083.
PMID: 39278946
The deleterious impact of antibiotics (ATB) on the microbiome negatively influences immune checkpoint inhibitors (ICI) response in patients with cancer. We conducted a randomized phase I study (EudraCT:2019-A00240-57) with 148...
4.
Montegut L, Liu P, Zhao L, Perez-Lanzon M, Chen H, Mao M, et al.
Mol Cancer
. 2024 Sep;
23(1):187.
PMID: 39242519
Background: The plasma concentrations of acyl coenzyme A binding protein (ACBP, also known as diazepam-binding inhibitor, DBI, or 'endozepine') increase with age and obesity, two parameters that are also amongst...
5.
Elkrief A, Mendez-Salazar E, Maillou J, Vanderbilt C, Gogia P, Desilets A, et al.
NPJ Precis Oncol
. 2024 Jul;
8(1):143.
PMID: 39014160
Anti-PD(L)-1 inhibition combined with platinum doublet chemotherapy (Chemo-IO) has become the most frequently used standard of care regimen in patients with non-small cell lung cancer (NSCLC). The negative impact of...
6.
Derosa L, Iebba V, Alves Costa Silva C, Piccinno G, Wu G, Lordello L, et al.
Cell
. 2024 Jun;
187(13):3373-3389.e16.
PMID: 38906102
The gut microbiota influences the clinical responses of cancer patients to immunecheckpoint inhibitors (ICIs). However, there is no consensus definition of detrimental dysbiosis. Based on metagenomics (MG) sequencing of 245...
7.
Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng S, Young A, Ngiow S, et al.
Nat Immunol
. 2024 Mar;
25(5):925-926.
PMID: 38514890
No abstract available.
8.
Hes C, Desilets A, Tonneau M, El Ouarzadi O, De Figueiredo Sousa M, Bahig H, et al.
Oral Oncol
. 2023 Nov;
148:106623.
PMID: 38006691
Objectives: Chemoradiation (CRT) in patients with locally advanced head and neck squamous cell cancer (HNSCC) is associated with significant toxicities, including mucositis. The gut microbiome represents an emerging hallmark of...
9.
Duttagupta S, Hakozaki T, Routy B, Messaoudene M
Curr Oncol
. 2023 Nov;
30(11):9406-9427.
PMID: 37999101
The gastrointestinal microbiome has been shown to play a key role in determining the responses to cancer immunotherapy, including immune checkpoint inhibitor (ICI) therapy and CAR-T. In patients with non-small...
10.
Routy B, Lenehan J, Miller Jr W, Jamal R, Messaoudene M, Daisley B, et al.
Nat Med
. 2023 Nov;
30(2):604.
PMID: 37923839
No abstract available.